Clinical Trial

MSA-01 in Multiple System Atrophy

Study acronym: MSA-01_P3
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate whether MSA-01 slows the progression of multiple system atrophy (MSA) and to assess its safety. The primary question is: • Does MSA-01 slow the progression of motor impairment as measured by UMSARS Part 2 score? Participants will be randomly assigned to receive MSA-01 or placebo for 12 months. They will attend regular clinic visits for safety and efficacy assessments and record their medication use and any side effects in a diary.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-25.
Trial Details
NCT Number NCT07446894
Lead Sponsor Tokyo University
Collaborators: Nobelpharma
Conditions Multiple System Atrophy (MSA)
Enrollment 140 participants
Start Date 2026-02-09
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-04